These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 29020678)

  • 1. Ovarian Cancer: A Heterogeneous Disease.
    Kossaï M; Leary A; Scoazec JY; Genestie C
    Pathobiology; 2018; 85(1-2):41-49. PubMed ID: 29020678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
    Noske A
    Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian carcinoma pathology and genetics: recent advances.
    Gilks CB; Prat J
    Hum Pathol; 2009 Sep; 40(9):1213-23. PubMed ID: 19552940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†.
    Cook DP; Vanderhyden BC
    Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD147 in ovarian and other cancers.
    Yang H; Chen B
    Int J Gynecol Cancer; 2013 Jan; 23(1):2-8. PubMed ID: 23221648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.
    Gatius S; Cuevas D; Fernández C; Roman-Canal B; Adamoli V; Piulats JM; Eritja N; Martin-Satue M; Moreno-Bueno G; Matias-Guiu X
    Pathobiology; 2018; 85(1-2):35-40. PubMed ID: 28614814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.
    Lassus H; Butzow R
    Br J Cancer; 2007 May; 96(10):1621-2; author reply 1623-4. PubMed ID: 17437016
    [No Abstract]   [Full Text] [Related]  

  • 9. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
    Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early preinvasive lesions in ovarian cancer.
    Chene G; Lamblin G; Le Bail-Carval K; Chabert P; Bakrin N; Mellier G
    Biomed Res Int; 2014; 2014():639252. PubMed ID: 24804229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP).
    Fishman DA; Bozorgi K
    Cancer Treat Res; 2002; 107():3-28. PubMed ID: 11775458
    [No Abstract]   [Full Text] [Related]  

  • 12. Histologic subtypes of ovarian carcinoma: an overview.
    Soslow RA
    Int J Gynecol Pathol; 2008 Apr; 27(2):161-74. PubMed ID: 18317227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
    Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
    Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Histopathologic prognostic factors, serum markers and selected molecular biologic factors in ovarian carcinoma].
    Spacek J; Jílek P; Petera J; Tesarík Z
    Ceska Gynekol; 2002 Nov; 67(6):343-9. PubMed ID: 12661373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.
    Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Noske A; Weichert W; Buckendahl AC; Budczies J; Müller BM; Elwali NE; Dietel M; Denkert C
    Histopathology; 2009 May; 54(6):657-66. PubMed ID: 19438741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular portraits of intratumoral heterogeneity in human ovarian cancer.
    Choi YP; Shim HS; Gao MQ; Kang S; Cho NH
    Cancer Lett; 2011 Aug; 307(1):62-71. PubMed ID: 21481528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.
    Hauptmann S; Friedrich K; Redline R; Avril S
    Virchows Arch; 2017 Feb; 470(2):125-142. PubMed ID: 28025670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma.
    Sorbe B; Frankendal B; Veress B
    Obstet Gynecol; 1982 May; 59(5):576-82. PubMed ID: 7070728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer: markers of response.
    Na YJ; Farley J; Zeh A; del Carmen M; Penson R; Birrer MJ
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S21-9. PubMed ID: 19955910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of heterogeneity in ovarian carcinoma.
    Stănescu AD; Pleş L; Edu A; Olaru GO; Comănescu AC; Potecă AG; Comănescu MV
    Rom J Morphol Embryol; 2015; 56(4):1357-63. PubMed ID: 26743281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.